Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Forestviewon Jun 30, 2021 12:05pm
409 Views
Post# 33473404

Phase 3 Delay

Phase 3 DelaySo, see below for what Dan said.  Though things are opening up after Covid, there is likely a massive backlog...also, Nasdaq uplist is expected to be tied to a Phase 3 start, so eventhough it wasn't mentioned in the news release it's still happening.  Last thing - a CEO update is coming in a couple of weeks...

We will experience a 6-8 week delay due to new Covid-related restrictions in Ontario imposed on Phase 1 clinics in May (we now have to do the study in 3 waves rather than 2). And the FDA itself is behind on it’s timings for meeting. Say another 4 weeks. Putting these together means that we think it’s unlikely we’d get our meeting before Christmas. Tiny stuff, but it’s a retail stock market. We are focused on the big prize: positive Phase III and at the same time, partnering (look at our China Nuance deal). Not sure what you mean by ‘momentum’ – we’re not a promotional agency.
<< Previous
Bullboard Posts
Next >>